---
title: "BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286092733.md"
description: "The primary findings of Phase 3 CALIBRATE were recently revealed during a presentation at the 2026 ECE. The results showcased the fast and long-lasting advantages of encaleret in ADH1, including significant improvements across crucial clinical measures."
datetime: "2026-05-12T11:31:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286092733.md)
  - [en](https://longbridge.com/en/news/286092733.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286092733.md)
---

# BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1

The primary findings of Phase 3 CALIBRATE were recently revealed during a presentation at the 2026 ECE. The results showcased the fast and long-lasting advantages of encaleret in ADH1, including significant improvements across crucial clinical measures.

### Related Stocks

- [BBIO.US](https://longbridge.com/en/quote/BBIO.US.md)

## Related News & Research

- [BridgeBio helps spotlight ATTR-CM's hidden impact on women](https://longbridge.com/en/news/286571552.md)
- [BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches](https://longbridge.com/en/news/286199057.md)
- [VIRGINIA RETIREMENT SYSTEMS ET Al Increases Stock Holdings in BridgeBio Pharma, Inc. $BBIO](https://longbridge.com/en/news/286643939.md)
- [CVS Health: A Second Chance at Life Through Heart Transplant and Ongoing Care](https://longbridge.com/en/news/286777492.md)
- [Tenaya Therapeutics' Gene Therapy Data Highlights Early Heart Rhythm Improvements](https://longbridge.com/en/news/286580579.md)